Convertible Note Funding Round with Strong Investor Support

1 August 2025

Venous Stent B.V. today announced the successful completion of its initial funding round through a convertible loan note.

Venous Stent B.V., a Netherlands-based medtech company developing a next-generation iliac venous stent, today announced the successful completion of its initial funding round through a convertible loan note. The round received strong backing from both existing investors and new supporters, underscoring confidence in the company’s mission to transform treatment for complex venous disease.

The funds will be used to advance Venous Stent’s proprietary stent technology through key pre-clinical testing and preparations for first-in-human trials. Designed to address the anatomical challenges of deep venous conditions such as May-Thurner syndrome, deep vein thrombosis (DVT), and non-thrombotic iliac vein lesions (NIVLs), the Venous Stent system combines adaptability, durability, and precision to improve long-term outcomes for patients.

Darren Spencer, CEO of Venous Stent B.V., commented:
“We are delighted to have closed this round with the strong support of both our existing and new investors. Their confidence validates our vision and the significant need for innovation in venous disease treatment. This funding allows us to take the next crucial steps toward clinical trials and ultimately delivering a solution that addresses real-world challenges faced by physicians and patients.”

Venous Stent B.V. is building on decades of combined clinical, engineering, and commercial expertise within its leadership team, with a clear roadmap toward regulatory approvals in both Europe and the United States. The company aims to establish itself as a leader in venous stenting innovation, with a technology platform designed to meet the growing global demand for effective treatment of chronic venous insufficiency and related conditions.